BREAST CANCER IN YOUNG AGE IS AN ASSAMESE WOMEN INDEPENDENT PROGNOSTIC INDICATOR IN

Size: px
Start display at page:

Download "BREAST CANCER IN YOUNG AGE IS AN ASSAMESE WOMEN INDEPENDENT PROGNOSTIC INDICATOR IN"

Transcription

1 BREAST CANCER IN YOUNG AGE IS AN INDEPENDENT PROGNOSTIC INDICATOR IN ASSAMESE WOMEN Gayatri Gogoi MD Assistant Professor Deptt of Pathology Assam Medical College, Dibrugarh, Assam, India - gayatrigogoi303@gmail.com.

2 CO AUTHORS 1. MONDITA BORGOHAIN,MD 2. HIRANYA SAIKIA,,PhD 3. PROGNAN SAIKIA, MD 4. RAM KANTA HAZARIKA, MD Affiliations: I,III,IV Professors, Department of Pathology & II Associate professor, Department of Biostatistics Acknowledgement: Dr S A Fazal, Associate Professor, Department of Surgery Assam Medical College and Hospital, Dibrugarh, Assam, India

3 BACKGROUND Breast Cancer diagnosis at young age is an independent negative prognostic factor is a controversial issue. However many studies indicate that breast cancer in young women have unique clinicopathological characteristics than in the elderly.a disturbing trend in India is gradually more and more young women are suffering from breast cancer Agrup M, Stäl O, Olsen K, Winren S (2000). C-erbB-2 Over expression and survival in early onset breast cancer. Breast Cancer Res Treat, 63, 23-9

4 BACKGROUND:BREAST CANCER IN ASSAMESE WOMEN Hospital cancer registry data from two large centers of North eastern states of India namely Assam, showed incidence of 48% women belonged to younger than 40 years which constitute largest young breast cancer group affected women in India. Approximately 3.7% 7.5% of the total number of breast cancer patients diagnosed each year in the US [1, 2] and Western Europe [3 5] are younger than 40 years. So incidence of younger Assamese women affected in India is 6 to 12 times higher than US and western Europe C. K. Anders, R. Johnson, J. Litton, M. Phillips, and A. Bleyer, Breast cancer before age 40 years, Seminars in Oncology, vol. 36, no. 3, pp , D. P. Winchester, Breast cancer in young women, Surgical Clinics of North America, vol. 76, no. 2, pp , 1996.

5

6

7 AGE SHIFT: BREAST CANCER NOW MORE COMMON IN 30'S AND 40'S

8 BACKGROUND: SURVIVAL ISSUE, The over all 5 year survival for breast cancer has increased from 75% in 1970's to almost 89% presently USA. This means that, out of every 100 women with breast cancer in the US, 89 women are likely to survive for atleast 5 years. There are barely any similar statistics for India available, but a rough estimate from the PBCR and HBCCR reports is that, this figure is not even more than 60%. The most important reason is stated as being lack of awareness about breast cancer and screening of the same; more than 50% patients of breast cancer present in stages 3 and 4, and outcome is not as good as earlier stages.

9 PUBLISHED BY ASCO (AMERICAN SOCIETY OF CLINICAL ONCOLOGY) IN 2009 ON 5 YEAR SURVIVAL

10 BACKGROUND Many retrospective series and subset analyses of larger randomized trials have shown that young patients with BC have a poorer prognosis compared to older age at diagnosis.women of 40 years tend to have more triplenegative and fewer luminal A and B breast cancers tumors of higher grade, more extensive intraductal component, more lymphovascular invasion, more likely ER negative tumors and more often BRCA-1 or -2 germline mutations. - However some studies performed in Asia and Africa did not find a different prognosis of younger BC patients compared to the older counterparts suggest that regional differences may exist concerning the biology and prognosis of young M. A. Bollet, B. Sigal-Zafrani, V. Mazeau et al., Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women

11

12 GLOBAL COMPARISON OF MORTALITY United States, for the year 2012: 232,714 women were newly detected wth breast cancer and 43,909 women died. So roughly for every 5 or 6 women newly diagnosed with BC, one lady is dying China, for the year 2012: 187,213 women were newly detected with breast cancer and 47,984 women died. So roughly, in China, for every 4 women newly diagnosed with BC one lady is dying of it. India, for the year 2012: 144,937 women were newly detected with breast cancer and 70,218 women died of breast cancer So roughly, in India, for every 2 women newly diagnosed with BC one lady is dying

13 BACKGROUND So more studies are needed why Indian women 1 out of 2 die due to BC according to latest WHO 2012 survival report in a background of BC average age in Indian Population is less than 50 years and its prognostic factors. Detailed data about prognostic factors and treatment outcome in breast cancer are scarce in India and Asia continent as a whole S. Aebi, S. Gelber, M. Castiglione-Gertsch et al., Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? The Lancet, vol. 355, no. 9218, pp , 2000

14 AIMS AND OBJECTIVE The purpose of this study was to characterize the breast cancer of Assamese women by studying the clinico pathological parameters of operable Breast cancer with curative intend of this tertiary care hospital in Assam, North Eastern part of India. Compare the data between >44 years of age groups to <45 years, at time of diagnosis and assess their prognosis with Disease free survival analysis To understand whether young age alone is one of the poor prognostic factor

15 DECLARATIONS Ethical clearance from Institutional Ethical Committee for Human subject: Yes Conflicts of interest: None

16 MATERIALS AND METHODS[I] Study was done by both acquiring retrospective data for period of 2009 and 2010 from Department of Pathology, the prospectively recruiting breast cancer cases attending from January 2011 to December, 2013, at Assam Medical College of India. Eligibility criteria: Histologically confirmed cases of invasive BC and surgical treatment with lumpectomy surgery or mastectomy with curative intents. Patients admitted for palliative surgery excluded from the analysis. were

17 MATERIALS AND METHODS[II] Women with operable breast cancer clinically and pathologically. were assessed Gross Tumor details including size, H & E stained slides were examined by two pathologists independently for general histological diagnosis besides ascertaining invasiveness of tumor histological type Lymph node metastasis, Mitotic figure counts and Modified BRG grading, Lymphovascular invasion prior to IHC staining. Also representative tumor area were selected at the same time ER, PR, Her2neu expression, and Ki67 proliferation were evaluated by IHC Bloom HJG, Richardson WW. Histologic Grading and Prognosis in BC, Br J Cancer. 1957

18 MATERIALS AND METHODS[III] Staging procedures included were complete history and physical examination, laboratory assessments, and diagnostic bilateral mammogram. Where indicated, ultrasonography of the breast and abdomen, chest radiograph, and radionuclide bone scan were performed. Selected patients received magnetic resonance imaging (MRI) of the breast, computerized tomography (CT).

19 MATERIALS AND METHODS[IV]:TREATMENT Treatment consisted of modified radical mastectomy or lumpectomy treatment and radiation therapy. Adjuvant chemotherapy with cyclophosphamide, methothrexate and 5- fluorouracil (CMF) or adriamycin and cyclophosphamide (AC), and hormonal therapy with tamoxifen were given as indicated. The patients were followed up in 3-6 months prospectively for Disease free survival[dfs], recurrence or distant metastasis and death.

20 MATERIALS AND METHODS[V] The inclusion of prospective data was closed in December Clinicopathological variables, were compared with those for operable breast cancers of women <44 and aged > 45 years. Breast cancer was classified according to the International Union Against Cancer (UICC), Clinical pathological staging followed according to the American Joint Committee on Cancer (AJCC, 6th edition).

21 MATERIALS AND METHODS[VI] Sections with a thickness of four μm were cut from Formalin fixed paraffin embedded blocks and used for IHC. The clones of antibodies SP1, Y85, CB11 and SP 6 were used to evaluate the ER-a, PR, Her2neu status and Ki67 fraction. The Allred scoring system was used to assess the ER and PR status. In summary, a total Allred score was obtained by the summation of proportion score and intensity score. A total score of 2 or more was considered as positive; scores 0 and 1 were considered negative D. C. Allred, J. M. Harvey, M. Berardo, and G. M. Clark, Prognostic and predictive factors in breast cancer by immunohistochemical analysis, Modern Pathology, vol. 11, no. 2, pp , 1998

22 MATERIALS AND METHODS[VII] Her2 neu scoring was done according to ASCO guidelines as 0, 1+, 2+,3+, only 3+ was taken for treatment by transtuzumab. Though various authors used different criteria for counting in various malignancies but purpose of breast, it was counted like mitosis counting formula of BRG, so that it is easily comparable to mitotic count and can be analyzed effectively (Trihia H et al, 2003) M. Elizabeth H. Hammond; Daniel F. Hayes; Mitch Dowsett; American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer, Arch Pathol Lab Med. 2010;134:

23 STATISTICAL ANALYSIS The Chi square -test was used to test for statistically significant different proportions of clinicopathological features and treatment-related factors of patients 45 years versus >44 years by using SPSS software. P value less than was considered statistically significant.

24 RESULTS AND OBSERVATION A total of 543 cases were evaluated Study included 209 women diagnosed with BC under the age of 44 and women over 45 years were 334. Mean age of BC was 38 years in younger and 52 years in older group with a mean age difference is 14 years. Family history of breast cancer or ovarian cancer in blood relatives are slightly higher[10%] in younger age group than elder age group[7%] which is not statistically significant

25 Table -1 : Comparison of clinicopathological characteristics of Patients > 44 years and <45 years at diagnosis Characteristic > 44 < 45 P value Age Mean [SD] [ 3.79] 52.11[5.71] Median [Range] 38[27-44] 51[45-70] Menopausal status Premenopausal < 0.00 Postmenopausal Family history No cancer in blood relatives Other than breast in at least one blood relative Other than breast cancer in 39 at least one first degree relative Breast cancer or ovarian cancer in at least one blood relative Breast cancer or ovarian cancer in at least one first degree relative Unknown NS Histology NS IDC Non IDC NS-not significant

26 FAMILY HISTORY NOT SIGNIFICANT Family history of breast cancer or ovarian cancer in blood relatives are slightly higher[10%] in younger age group than elder age group[7%] which is not statistically significant No cancer in blood relatives other than breast in at least one blood relative other than breast cancer in least on first degree relative 10 7 Breast cancer on ovarian cancerin at least one blood relative 7 4 Breast caner or ovarian cancer inat least one first degree relative 44 45

27 Table -1 : Comparison of clinicopathological characteristics of Patients > 44 years and <45 at diagnosis Charactertics > 44 < 45 P value T stage <0.00 T0 Nil Nil T T T T Tx Nil Nil N stage < 0.00 N N N N Nx Nil Nil M stage NS M M Mx 22 28

28 RESULTS When comparing Tumour sizes, T stages in >44 age groups have higher degree of T2 tumour [58%] than <45 age groups[41%] But <45 age group women had more T3 tumour - 35% in contrast to 11% in younger. Younger counterpart presented without axillary node 22% vs 39% in other.it means young women presented more frequently[78%] with positive nodes Whereas younger group were presented at diagnosis without metastasis in 41% women and older group with 33%.

29 Table -1 : Comparison of clinicopathological characteristics of Patients > 44 years and <45 at diagnosis Charactertics > 44 < 45 P value AJCCStage NS I II III Unknown BR Grading <0.00 G G G Gx NIL NIL Lymphovascular invasion(lv) NS LV LV Unknown Type of surgery Lumpectomy MRM

30 RESULTS In AJCC staging 58% of grade II tumours were seen younger counterpart whereas in older, common presentation at time of diagnosis was 51 % Grade III tumours. It didn t show any statistically significant relationship Comparing Bloom Richardson Histologic Grade, younger Assamese women were more frequently presented with a tumour with higher grade which accounts to 64% than 43% in older group. It showed a statistically significant relationship with P value less than Lymphovascular invasion though marginally higher in younger women but it had no significant relation

31 Table -1 : Comparison of clinicopathological characteristics of Patients > 44 years and <45 at diagnosis Charactertics > 44 < 45 P value Estrogen receptor(er) status <0.00 ER negative ER Positive Unknown Progesterone receptor (PR) status <0.00 PR negative PR positive Unknown Her2neu status NS Her2neu negative Her2neu positive Unknown NS=not significant

32 ER+, Allred score 8/8 Luminal A: tubululobular histology

33 Her2 neu-3+ Ki67 high expression

34 RESULTS AND INTERPRETATIONS o IHC analysis for ER and PR showed very low ER and PR expression in young age[28%, 27%] group which is a complete opposite in elder group with higher expression 73%. It indicated a significant statistical correlation with P value less than Her2 neu status was similar in both the group s[19%, 20%] Ki67 expression for degree of proliferation showed high grades are more frequent[57%] in younger age group whereas for elder group moderate grade of proliferation is common[53%]

35 Table -1 : Comparison of clinicopathological characteristics of Patients > 44 years and <45 at diagnosis Charactertics > 44 < 45 P value Tumor subtype <0.001 Luminal A Luminal B Her2 overexpressing Triple negative Unknown Adjuvant Chemotherapy Yes NO Adjuvant Tamoxifen Yes 64 [30%] 207[61%] No 145 [ 70%] 127 [39%] DFS[2 yrs] 174[83%] 304[91%] Disease free survival=dfs

36 RESULTS AND INTERPRETATIONS While analyzing tumour subtypes elder age group had 51% Luminal A whereas Younger women only 12%. Younger women tumours were belonged to triple negative type in 50% which is far above the level of 12% in other group.tumour types correlation showed a statistically significant relationship. Women age <44 were treated more frequently with chemotherapy[78%] than >45 age group where this group received Tamoxifen more commonly 61% in contrast to 30% in other group. When compared for disease free survival [DFS]of two years younger women recorded more disease related events than with 83% than elder counterpart with 91%.

37 1

38 DISCUSSION & OBSERVATION[I] A total of 543 Assamese Indian women diagnosed with BC was analyzed, but some of women could not be evaluated in some parameters or others clinically, histopathologically Immunohistochemically or completely followed up due to certain limitations specially in retrospective cases. Our study showed 38% affected in <44 years age group with median range of years which were mostly premenopausal excepting a few. This is very comparable to the data of Hospital Based Tumour Registry of this region. BC in younger age found to be many times higher in Assamese Indian than American Women and European Women.

39 DISCUSSION[II] But the mean age of >45 year category was only 52 years. Which means overall scenario of breast cancer is common among young Assamese and Indian Women which is similar to study, Saxena et al and Gogoi et al.2012 Understanding the average menopausal age of study population, cases were divided as <44 and >45, our study showed 90% cases attained menopause by 45 years Saxena et al. Clinico-morphological patterns of breast cancer including family history in a New Delhi hospital, India-A crosssectional study, World Journal of Surgical Oncology 2005, 3:67

40 DISCUSSION & OBSERVATIONS[III] Our study did not reveal any significant family history of breast or ovarian cancer in blood relatives with 10% than 7% in other similar to studies like Rudat et al When observing the data of both younger and elder, commonest size of tumour at the time of diagnosis T2 [2-5 cm in size] 58% and 41% respectively T. Aryandono, Harijadi, and Soeripto, Breast cancer in young women: prognostic factors and clinicopathological features, Asian Pacific Journal of Cancer Prevention, vol. 7, no. 3, pp , 2006

41 DISCUSSION[III] Our data showed that young age is an independent prognostic factor of breast cancer patients similar to study, Rudat et al 2012 Breast cancer in young age under 44 years old mostly belonged to T2 stage, higher positive Axillary lymph node, higher grade, which is similar to findings of Sundquist et al[2001] and Aryandono et al,2006. Similarity was found in Sundquist s study that the proportion of grade 3 tumors decreased with age (Sundquist et al. in contrast to Aryandono et al,2006 study without this significance Sundquist M, Thorestenson S, Brenden L, Wingren S, Nordenskjold B (2001). Incidence and prognosis in early onset breast cancer.the Breast, 11, 30-5.

42 60 58 T stage Series T0 T1 T2 T3 T4 Tx 0 0

43 DISCUSSION It showed that tumor in young age had high proliferation activity which was studied by Ki67 expression pattern which also validate findings of Gogoi et al 2014 from same tertiary care centre. Our findings in younger group showed lower ER positive tumours[27%] than >45 age group with 73% which is comparable with papers in the literature (Sidoni et al.,2003; Daidone et al., 2003) that usually older women with breast cancer has higher positivity of ER & PR. This group of young patients is not likely response to hormonal treatment or manipulation and they belonged to TNBC or Her2 over expressed category

44 G3 TUMOURS DECREASE WITH AGE BR Grading G1 G2 G3

45 HER2 EXPRESSION IN VARIOUS STUDIES younger age older age Agrup et al 27% Rudrigues et al. 48% 28% Aryndono et al 74% 55% Our study 20% 19%

46 DISCUSSION Her2 expression was 20% in younger women which was almost similar to elderly with group 19% expression. it was observed that this group of patient associated with other poor prognostic factors. While looking at lympho vascular invasion in tumour, it did not reveal any significant trend between two categories. In both the groups equal women underwent lumpectomy[16%] and MRM[84%] As young women were mostly negative for ER and PR, and also large numbers of them were node positive so they were given adjuvant chemotherapy[77%]. Adjuvant chemotherapy was given along with tamoxifen to >45 group also as good numbers of then were belonged to node positive category.

47 80 80 Adjuvant Chemotherapy Adjuvant Tamoxifen Yes No Yes NO

48 DISCUSSION As this is a ongoing study, 5 year survival outcome are yet to be completed, we have of 2 years data of DFS which showed 83% in younger group than 91% of older group. So this trend is definitely showing a poorer prognosis to younger women category The breast cancer in young women< 44 showed more aggressive phenotype than >45, although the later group usually diagnosed in more advanced stage, AJCC stage in 41%.

49 80 74 AJCCStage I II III Unknown

50 40 40 N stage N0 N1 N2 N3

51 . DISCUSSION It was observed that BC in young women showed higher proliferation rate than elderly group, also they had lower positivity for ER &PR with higher TNBC. They received adjuvant chemotherapy more commonly than tamoxifen. The recurrence,metastasis and death were still higher in young than elderly patients. It seemed that BC in young and older women has different biologic behaviour, and further research is needed.

52 60 Tumor subtype Luminal A Luminal B Her2 overexpressing Triple negative

53 70 M stage 66 DFS[2 yrs] DFS[2 yrs] M0 M

54 Younger age women prognostic factors which could be of more 50 taken into consideration is TNBC and high proliferation 40 fraction in tumour cells. Higher proliferation of tumours likely to be linked to age and hence poorer survival Ki67 pattern High Medium Low

55 DISCUSSION But when strongest prognostic factors like nodes and metastasis are considered, they were no significant difference between two groups. Still taking that background, two years disease free survival was taking a poorer outcome in compared to >45 group of Assamese women. So young age itself is a independent prognostic indicator over and above standard predictive and prognostic criteria. This is a ongoing study, 5 years survival outcome will complete 2018.

56 CONCLUSION & FUTURE PERSPECTIVE Patients 44 years exhibited more often triple negative and less frequently luminal A tumors compared to patients >45 years. Moreover in general, BC is frequent in much young age group in Assamese Indian women, poor survival may not be only due to presentation in advanced stage, likely contribution of poor survival due to young age factor which determines disease aggression which was observed in the study

57 FUTURE PERSPECTIVE One project funded by Indian council of Medical Research is going on study of types of breast cancer on Assamese women with special emphasis on TNBC Another ICMR approved project is about to begin on germline mutation spectra on BRCA mutation 1 and BRCA 2 genes in multi ethnic breast cancer patients from North eastern India based on sequencing.

58 This world is moved not only by the mighty shoves of the heroes but also by the aggregates of the tiny pushes of each honest worker. Hellen Killer

59 59

60 Sunita Saxena, Bharat Rekhi, Anju Bansal, Ashok Bagga, Chintamani, and Nandagudi S Murthy Clinico-morphological patterns of breast cancer including family history in a New Delhi hospital, India-A cross-sectional study, World Journal of Surgical Oncology 2005, 3:67 M. Elizabeth H. Hammond; Daniel F. Hayes; Mitch Dowsett; American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer, Arch Pathol Lab Med. 2010;134:

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers 日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu

More information

Clinical pathological and epidemiological study of triple negative breast cancer

Clinical pathological and epidemiological study of triple negative breast cancer International Journal of Research in Medical Sciences Ajay A et al. Int J Res Med Sci. 217 Jun;5(6):2657-2661 www.msjonline.org pissn 232-71 eissn 232-12 Original Research Article DOI: http://dx.doi.org/1.1823/232-12.ijrms2172465

More information

Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression

Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta

More information

RESEARCH ARTICLE. Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India

RESEARCH ARTICLE. Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India APJCP.2016.17.6.2995 RESEARCH ARTICLE Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India Dinesh Chandra Doval 1,2 *, P Suresh 1, Rupal Sinha 2, Saud Azam 2, Ullas Batra

More information

Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine

Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following

More information

Time to Start Adjuvant Systemic Treatment in Breast Cancer; a Retrospective Cohort Study

Time to Start Adjuvant Systemic Treatment in Breast Cancer; a Retrospective Cohort Study Cancer and Clinical Oncology; Vol. 6, No. 2; 2017 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Time to Start Adjuvant Systemic Treatment in Breast Cancer; a Retrospective

More information

Her-2/neu expression and its correlation with ER status and various clinicopathological parameters

Her-2/neu expression and its correlation with ER status and various clinicopathological parameters Original Research Article DOI: 10.5958/2394-6792.2016.00106.X Her-2/neu expression and its correlation with ER status and various clinicopathological parameters Kriti Chauhan 1,*, Monika Garg 2, Abhimanyu

More information

The Expression of Basal Cytokeratins in Breast Cancers

The Expression of Basal Cytokeratins in Breast Cancers Global Journal of Medical Research: C Microbiology and Pathology Volume 17 Issue 2 Version 1.0 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online

More information

Surgery for Breast Cancer

Surgery for Breast Cancer Surgery for Breast Cancer 1750 Mastectomy - Petit 1894 Radical mastectomy Halsted Extended, Super radical mastectomy 1948 Modified radical mastectomy Patey 1950-60 WLE & RT Baclesse, Mustakallio 1981-85

More information

Case Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.

Case Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions. Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to

More information

Prediction of Postoperative Tumor Size in Breast Cancer Patients by Clinical Assessment, Mammography and Ultrasonography

Prediction of Postoperative Tumor Size in Breast Cancer Patients by Clinical Assessment, Mammography and Ultrasonography Prediction of Postoperative Tumor Size in Breast Cancer Patients by Clinical Assessment, Mammography and Ultrasonography Eyad Fawzi AlSaeed 1 and Mutahir A. Tunio 2* 1 Consultant Radiation Oncology, Chairman

More information

Breast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined

Breast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases

More information

Overview of breast cancerpatients and their prognostic factors treated in Baghdad teaching hospital/ oncology department in the year 2010

Overview of breast cancerpatients and their prognostic factors treated in Baghdad teaching hospital/ oncology department in the year 2010 Original Article Overview of breast cancerpatients and their prognostic factors treated in Baghdad teaching hospital/ oncology department in the year 21 * DMRT clinical oncology, MSc. pathology. Summary:

More information

Breast Cancer. Saima Saeed MD

Breast Cancer. Saima Saeed MD Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast

More information

Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05

Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05 Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan

More information

Ductal Carcinoma-in-Situ: New Concepts and Controversies

Ductal Carcinoma-in-Situ: New Concepts and Controversies Ductal Carcinoma-in-Situ: New Concepts and Controversies James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation

More information

4/13/2010. Silverman, Buchanan Breast, 2003

4/13/2010. Silverman, Buchanan Breast, 2003 Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk

More information

DOCTORAL THESIS SUMMARY

DOCTORAL THESIS SUMMARY UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA FACULTY OF MEDICINE DOCTORAL THESIS SUMMARY CLINICO-IMAGING STUDY OF INVASIVE DUCTAL BREAST CARCINOMAS CORRELATED TO HORMONAL RECEPTORS AND HER2/NEU ONCOPROTEIN

More information

Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy

Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy Case Series Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy Ling Xu 1*, Fang Li 1,2*, Yinhua Liu 1, Xuening Duan 1, Jingming Ye 1,

More information

Hormone receptor sensitivity in Breast Cancer patients in Pune city of Maharashtra State, India A retrospective study

Hormone receptor sensitivity in Breast Cancer patients in Pune city of Maharashtra State, India A retrospective study International Journal of Advanced Biotechnology and Research(IJBR) ISSN 0976-2612, Online ISSN 2278 599X, Vol 6, Issue2, 2015, pp196-202 http://www.bipublication.com Research Article Hormone sensitivity

More information

Breast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD

Breast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast

A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast Original Research Article A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast E. Rajesh Goud 1, M. Muralidhar 2*, M. Srinivasulu 3 1Senior

More information

A Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer

A Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer Elmer ress Original Article World J Oncol. 2017;8(3):71-75 A Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer Hui Hu a, Wei Wei a, Xin Yi a, Ling Xin

More information

Clinico- Pathological Features And Out Come Of Triple Negative Breast Cancer

Clinico- Pathological Features And Out Come Of Triple Negative Breast Cancer Clinico- Pathological Features And Out Come Of Triple Negative Breast Cancer Dr. HassanAli Al-Khirsani, MBChB, CABM, F.I.C.M.S AL-Sadder teaching hospital, oncology unit Dr. Nasser Ghaly Yousif, MBChB,G.P.

More information

Results of the ACOSOG Z0011 Trial

Results of the ACOSOG Z0011 Trial DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival

More information

UK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin

UK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University

More information

A Study on Importance of Molecular Subtyping As a Prognostic Indicator of Breast Carcinoma

A Study on Importance of Molecular Subtyping As a Prognostic Indicator of Breast Carcinoma IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 79-8, p-issn: 79-86.Volume 8, Issue Ser. (January. 9), PP - www.iosrjournals.org A Study on Importance of Molecular Subtyping As a Prognostic

More information

SCIENCE CHINA Life Sciences

SCIENCE CHINA Life Sciences SCIENCE CHINA Life Sciences RESEARCH PAPER April 2013 Vol.56 No.4: 335 340 doi: 10.1007/s11427-013-4435-y Risk factors of recurrence in small-sized, node negative breast cancer in young women: a retrospective

More information

Breast Imaging: Multidisciplinary Approach. Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina

Breast Imaging: Multidisciplinary Approach. Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina Breast Imaging: Multidisciplinary Approach Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina No Disclosures Objectives Discuss a multidisciplinary breast

More information

PMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center

PMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic

More information

Understanding and Optimizing Treatment of Triple Negative Breast Cancer

Understanding and Optimizing Treatment of Triple Negative Breast Cancer Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology Program Leader, Gastrointestinal Oncology Department

More information

Triple Negative Breast Cancer

Triple Negative Breast Cancer Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional

More information

Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer

Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Kathy S. Albain, MD, FACP Professor of Medicine Dean s Scholar Loyola University Chicago Stritch School of Medicine Cardinal Bernardin

More information

Breast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?

Breast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment? Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen

More information

Basement membrane in lobule.

Basement membrane in lobule. Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.

More information

Breast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital

Breast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant

More information

The Clinical Significance of. Triple-negative Phenotype on. Cancer Patients

The Clinical Significance of. Triple-negative Phenotype on. Cancer Patients The Clinical Significance of Triple-negative Phenotype on Prognosis of Young Age( 35) Breast Cancer Patients IM-KYUNG KIM Department of Medicine The Graduate School, Yonsei University The Clinical Significance

More information

One Breast Cancer Annual Report

One Breast Cancer Annual Report One 2015 Breast Cancer Annual Report One OVERVIEW The Breast Program at Carolinas HealthCare System s Levine Cancer Institute, offers comprehensive care. Patients with benign and malignant disease of the

More information

HEALTH CARE DISPARITIES. Bhuvana Ramaswamy MD MRCP The Ohio State University Comprehensive Cancer Center

HEALTH CARE DISPARITIES. Bhuvana Ramaswamy MD MRCP The Ohio State University Comprehensive Cancer Center HEALTH CARE DISPARITIES Bhuvana Ramaswamy MD MRCP The Ohio State University Comprehensive Cancer Center Goals Understand the epidemiology of breast cancer Understand the broad management of breast cancer

More information

Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience

Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell

More information

Tata Memorial Centre s opinion is summarized as follows:

Tata Memorial Centre s opinion is summarized as follows: February 2 nd 2015 Dear Ms., Thank you for reaching out to Tata Memorial Centre for an expert opinion in regard to assessing your treatment options. Navya Network is pleased to offer this online consultation

More information

Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country

Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country DOI 10.1007/s00268-015-3133-2 ORIGINAL SCIENTIFIC REPORT Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country

More information

Spectrum of breast cancer patients: twin institutional study

Spectrum of breast cancer patients: twin institutional study International Surgery Journal Nichkaode PB et al. Int Surg J. 2017 Sep;4(9):3077-3082 http://www.ijsurgery.com pissn 2349-3305 eissn 2349-2902 Original Research Article DOI: http://dx.doi.org/10.18203/2349-2902.isj20173891

More information

Breast Cancer. Dr. Andres Wiernik 2017

Breast Cancer. Dr. Andres Wiernik 2017 Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk

More information

Adjuvan Chemotherapy in Breast Cancer

Adjuvan Chemotherapy in Breast Cancer Adjuvan Chemotherapy in Breast Cancer Prof Dr Adnan Aydıner Istanbul University, Oncology Institute aa1 Slide 1 aa1 adnan aydiner; 17.02.2008 15-Year Reductions in Recurrence and Disease-Specific Mortality

More information

Breast Cancer? Breast cancer is the most common. What s New in. Janet s Case

Breast Cancer? Breast cancer is the most common. What s New in. Janet s Case Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of

More information

Epidemiology and receptor status distribution in a cohort of carcinoma breast patients presenting in our institution

Epidemiology and receptor status distribution in a cohort of carcinoma breast patients presenting in our institution Original Research Article Epidemiology and receptor status distribution in a cohort of carcinoma breast patients presenting in our institution K. Muthu Raj MS 1, S. Mathan Sankar 2* 1 Associate Professor,

More information

Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in New Delhi, India

Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in New Delhi, India DOI:http://dx.doi.org/10.7314/APJCP.2015.16.12.4959 Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in New Delhi, India RESEARCH ARTICLE Immunohistochemical Profile of

More information

Contemporary Classification of Breast Cancer

Contemporary Classification of Breast Cancer Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline

More information

Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients

Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, December 2015. Vol. 12(3), 2221-2225 Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients S.M. Hosseini¹, H. Shahbaziyan

More information

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors

More information

Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.

Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides

More information

Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer

Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer Hee Jung Kwon, Nuri Jang, Min Hui Park, Young Kyung Bae Department of Pathology, Yeungnam

More information

Carcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS

Carcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS Carcinoma mammario: le istologie non frequenti Valentina Guarneri Università di Padova IOV-IRCCS Histological diversity of breast adenocarcinomas Different histological types are defined according to specific

More information

Intro to Cancer Therapeutics

Intro to Cancer Therapeutics An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro

More information

Evolving Practices in Breast Cancer Management

Evolving Practices in Breast Cancer Management Evolving Practices in Breast Cancer Management The Georgia Tumor Registrars Association 2016 Priscilla R. Strom, MD, FACS Objectives 1. understand newer indications for neoadjuvant treatment 2. understand

More information

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research   ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Ki-67 Expression and Its Association with Conventional Prognostic Markers in Bhagyashri R Hungund

More information

ESMO Breast Cancer Preceptorship Singapore November Special Issues in Treatment of Young Women with Breast Cancer

ESMO Breast Cancer Preceptorship Singapore November Special Issues in Treatment of Young Women with Breast Cancer ESMO Breast Cancer Preceptorship Singapore November 2017 Special Issues in Treatment of Young Women with Breast Cancer Prudence Francis MD Peter MacCallum Cancer Centre Melbourne, Australia Conflict of

More information

Molecular Characterization of Breast Cancer: The Clinical Significance

Molecular Characterization of Breast Cancer: The Clinical Significance Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville

More information

Diseases of the breast (2 of 2) Breast cancer

Diseases of the breast (2 of 2) Breast cancer Diseases of the breast (2 of 2) Breast cancer Epidemiology & etiology The most common type of cancer & the 2 nd most common cause of cancer death in women 1 of 8 women in USA Affects 7% of women Peak at

More information

Insights and Updates in Breast Cancer. No Disclosures. Learning Objectives. Mountain States Cancer Conference 2017 Regina Jeanise Brown MD

Insights and Updates in Breast Cancer. No Disclosures. Learning Objectives. Mountain States Cancer Conference 2017 Regina Jeanise Brown MD Insights and Updates in Breast Cancer Mountain States Cancer Conference 2017 Regina Jeanise Brown MD 10/14/17 No Disclosures Learning Objectives Understand screening recommendations Understand the effectiveness

More information

Department of Endocrine & Breast Surgery Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India

Department of Endocrine & Breast Surgery Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India Department of Endocrine & Breast Surgery Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India Evidence-Based Pragmatic SGPGI Breast Cancer Management Protocols (Summary) Background:

More information

The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer

The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate

More information

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed

More information

What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine

What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine What is Cancer? Layman s terms: cancer starts when cells grow out of control (in any place in the body) and crowd out normal cells

More information

Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011

Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Robert W. Carlson, M.D. Professor of Medicine Stanford University Chair, NCCN Breast Cancer Treatment Guidelines Panel Selection of

More information

Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint

Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical

More information

Breast cancer staging update. Ekaterini Tsiapali, MD, FACS MedStar Regional Breast Program Site Director

Breast cancer staging update. Ekaterini Tsiapali, MD, FACS MedStar Regional Breast Program Site Director Breast cancer staging update Ekaterini Tsiapali, MD, FACS MedStar Regional Breast Program Site Director 1 1 Review of the AJCC 8 th edition breast cancer staging Review of genomic assays as stage modifiers

More information

RESEARCH ARTICLE. Abstract. Introduction

RESEARCH ARTICLE. Abstract. Introduction DOI:http://dx.doi.org/10.7314/APJCP.2014.15.18.7959 Comparison of Single Hormone Receptor Positive and Double Hormone Receptor Positive Breast Cancers RESEARCH ARTICLE Do Clinical Features and Survival

More information

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed

More information

ORIGINAL ARTICLE The value of Nottingham grade in breast cancer re-visited in the Sri Lankan setting

ORIGINAL ARTICLE The value of Nottingham grade in breast cancer re-visited in the Sri Lankan setting Malaysian J Pathol 2017; 39(2) : 141 148 ORIGINAL ARTICLE The value of Nottingham grade in breast cancer re-visited in the Sri Lankan setting Harshini PEIRIS PhD, Lakmini MUDDUWA MBBS, MD*, Neil THALAGALA

More information

Research Article Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67

Research Article Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67 SAGE-Hindawi Access to Research International Breast Cancer Volume 20, Article ID 47957, 4 pages doi:0.406/20/47957 Research Article Stromal Expression of CD0 in Invasive Breast Carcinoma and Its Correlation

More information

Breast Cancer Breast Managed Clinical Network

Breast Cancer Breast Managed Clinical Network Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive

More information

Research Article The Effect of Young Age in Hormone Receptor Positive Breast Cancer

Research Article The Effect of Young Age in Hormone Receptor Positive Breast Cancer BioMed Research International Volume 2015, Article ID 325715, 6 pages http://dx.doi.org/10.1155/2015/325715 Research Article The Effect of Young Age in Hormone Receptor Positive Breast Cancer Minna K.

More information

EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino

EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT

More information

Morphological and Molecular Typing of breast Cancer

Morphological and Molecular Typing of breast Cancer Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological

More information

Survival of Triple Negative versus Triple Positive Breast Cancers: Comparison and Contrast

Survival of Triple Negative versus Triple Positive Breast Cancers: Comparison and Contrast 10.14456/apjcp.2016.191/APJCP.2016.17.8.3911 Survival of Triple Negative and Triple Positive Breast Cancers RESEARCH ARTICLE Survival of Triple Negative versus Triple Positive Breast Cancers: Comparison

More information

Measure Definition Benchmark Endorsed By. Measure Definition Benchmark Endorsed By

Measure Definition Benchmark Endorsed By. Measure Definition Benchmark Endorsed By Process Risk Assessment Tumor Site: Breast Process Presence or Risk absence Assessment of cancer in first-degree blood relatives documented in patients with invasive breast Presence cancer or absence of

More information

RESEARCH ARTICLE. Wan Faiziah Wan Abdul Rahman 1 *, Mohd Hashairi Fauzi 2, Hasnan Jaafar 1. Abstract. Introduction

RESEARCH ARTICLE. Wan Faiziah Wan Abdul Rahman 1 *, Mohd Hashairi Fauzi 2, Hasnan Jaafar 1. Abstract. Introduction RESEARCH ARTICLE Expression of DNA Methylation Marker of Paired-Like Homeodomain Transcription Factor 2 and Growth Receptors in Invasive Ductal Carcinoma of the Breast Wan Faiziah Wan Abdul Rahman 1 *,

More information

Heather M. Gage, MD, Avanti Rangnekar, Robert E. Heidel, PhD, Timothy Panella, MD, John Bell, MD, and Amila Orucevic, MD, PhD

Heather M. Gage, MD, Avanti Rangnekar, Robert E. Heidel, PhD, Timothy Panella, MD, John Bell, MD, and Amila Orucevic, MD, PhD HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF CLINICAL TRIALS Heather M. Gage, MD, Avanti Rangnekar,

More information

SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER

SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Sunil Shrestha 1*, Ji Yuan Yang, Li Shuang and Deepika Dhakal Clinical School of Medicine, Yangtze University, Jingzhou, Hubei Province, PR. China Department

More information

Figure 1: PALLAS Study Schema. Endocrine adjuvant therapy may have started before randomization and be ongoing at that time.

Figure 1: PALLAS Study Schema. Endocrine adjuvant therapy may have started before randomization and be ongoing at that time. Figure 1: PALLAS Study Schema Endocrine adjuvant therapy may have started before randomization and be ongoing at that time. Approximately 4600 patients from approximately 500 global sites will be randomized

More information

My Personalized Breast Cancer Worksheet

My Personalized Breast Cancer Worksheet My Personalized Breast Cancer Worksheet KNOW For Early-Stage Breast Cancer. No Questions. Only Results. No two tumors are alike. What are the characteristics of your breast cancer and how will that effect

More information

Breast Cancer Diagnosis, Treatment and Follow-up

Breast Cancer Diagnosis, Treatment and Follow-up Breast Cancer Diagnosis, Treatment and Follow-up What is breast cancer? Each of the body s organs, including the breast, is made up of many types of cells. Normally, healthy cells grow and divide to produce

More information

The Oncotype DX Assay A Genomic Approach to Breast Cancer

The Oncotype DX Assay A Genomic Approach to Breast Cancer The Oncotype DX Assay A Genomic Approach to Breast Cancer Pathology: 20 th and 21 st Century Size Age Phenotype Nodal status Protein/Gene Genomic Profiling Prognostic & Predictive Markers Used in Breast

More information

Clinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer

Clinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer Original Articles Jpn J Clin Oncol 2012;42(6)471 476 doi:10.1093/jjco/hys046 Advance Access Publication 3 April 2012 Clinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer Junnan Li,

More information

FAQs for UK Pathology Departments

FAQs for UK Pathology Departments FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have

More information

The effect of delayed adjuvant chemotherapy on relapse of triplenegative

The effect of delayed adjuvant chemotherapy on relapse of triplenegative Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,

More information

The TAILORx Trial: A review of the data and implications for practice

The TAILORx Trial: A review of the data and implications for practice The TAILORx Trial: A review of the data and implications for practice Angela DeMichele, MD, MSCE Jill & Alan Miller Endowed Chair in Breast Cancer Excellence Professor of Medicine and Epidemiology University

More information

What is the recommended regimen for adjuvant radiation therapy? Tata Memorial Centre s opinion is summarized as follows:

What is the recommended regimen for adjuvant radiation therapy? Tata Memorial Centre s opinion is summarized as follows: February 3 rd 2015 Dear Ms., Thank you for reaching out to Tata Memorial Centre for an expert opinion in regard to assessing your treatment options. Navya Network is pleased to offer this online consultation

More information

Hormone receptor and Her2 neu (Her2) analysis

Hormone receptor and Her2 neu (Her2) analysis ORIGINAL ARTICLE Impact of Triple Negative Phenotype on Breast Cancer Prognosis Henry G. Kaplan, MD* and Judith A. Malmgren, PhD à *Swedish Cancer Institute at Swedish Medical Center; HealthStat Consulting

More information

ORIGINAL RESEARCH PAPER

ORIGINAL RESEARCH PAPER Dr. Mathan Sankar. S Dr. T. Babu Antony* ABSTRACT ORIGINAL RESEARCH PAPER INCIDENCE AND CLINICO PATHOLOGICAL FEATURES OF TRIPLE NEGATIVE RECEPTORS STATUS IN CARCINOMA BREAST IN OUR INSTITUTION General

More information

OUTLINE PAST PRESENTFUTURE BREAST CANCER INCIDENCE AND MORTALITY CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM

OUTLINE PAST PRESENTFUTURE BREAST CANCER INCIDENCE AND MORTALITY CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM OUTLINE CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM October 11, 2014 SARA M GARRIDO, M.D., F.A.C.P Chief Medical Officer at AMS Miami, October 11, 2014 PAST PRESENTFUTURE -BRIEF

More information

W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability

W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability Background: The key issue is to investigate whether some of the data

More information

Validity of St Gallen risk categories in prognostication of breast cancer patients in Southern Sri Lanka

Validity of St Gallen risk categories in prognostication of breast cancer patients in Southern Sri Lanka Peiris et al. BMC Women's Health (2018) 18:30 DOI 10.1186/s12905-018-0524-1 RESEARCH ARTICLE Open Access Validity of St Gallen risk categories in prognostication of breast cancer patients in Southern Sri

More information

Surgical Pathology Issues of Practical Importance

Surgical Pathology Issues of Practical Importance Surgical Pathology Issues of Practical Importance Anne Moore, MD Medical Oncology Syed Hoda, MD Surgical Pathology The pathologist is central to the team approach needed to manage the patient with breast

More information

BREAST CANCER BREAST CANCER

BREAST CANCER BREAST CANCER BREAST CANCER George Raptis, M.D., M.B.A Division of Medical Oncology & Hematology College of Physicians & Surgeons Columbia University BREAST CANCER Epidemiology - Commonest cancer in women - About 235,000

More information